Comparing Drug Images and Repurposing Drugs with BioGPS and FLAPdock: The Thymidylate Synthase Case
暂无分享,去创建一个
Francesca Spyrakis | Maria Paola Costi | Gabriele Cruciani | Lydia Siragusa | Stefania Ferrari | Rosaria Luciani | Lydia Siragusa | F. Spyrakis | G. Cruciani | R. Luciani | Chiara Borsari | S. Ferrari | Chiara Borsari
[1] Yoshihiro Yamanishi,et al. Relating drug–protein interaction network with drug side effects , 2012, Bioinform..
[2] Jian Wang,et al. In Silico Elucidation of the Molecular Mechanism Defining the Adverse Effect of Selective Estrogen Receptor Modulators , 2007, PLoS Comput. Biol..
[3] D. Santi,et al. The catalytic mechanism and structure of thymidylate synthase. , 1995, Annual review of biochemistry.
[4] Raymond Lo,et al. Raloxifene attenuates Pseudomonas aeruginosa pyocyanin production and virulence. , 2012, International journal of antimicrobial agents.
[5] Shuxing Zhang,et al. Polypharmacology: drug discovery for the future , 2013, Expert review of clinical pharmacology.
[6] M. Mori,et al. Histone demethylating agents as potential S-adenosyl-L-methionine-competitors , 2016 .
[7] Stefano Alcaro,et al. A Pipeline To Enhance Ligand Virtual Screening: Integrating Molecular Dynamics and Fingerprints for Ligand and Proteins , 2015, J. Chem. Inf. Model..
[8] A. Bairoch,et al. The SWISS-PROT protein sequence data bank: current status. , 1994, Nucleic acids research.
[9] Weijun Xu,et al. Repurposing Registered Drugs as Antagonists for Protease-Activated Receptor 2 , 2015, J. Chem. Inf. Model..
[10] Paul T. Groth,et al. Drug discovery FAQs: workflows for answering multidomain drug discovery questions. , 2015, Drug discovery today.
[11] S. Moro,et al. Toward the rational design of protein kinase casein kinase-2 inhibitors. , 2002, Pharmacology & therapeutics.
[12] G. Peters,et al. The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells , 2014, Cancer Chemotherapy and Pharmacology.
[13] Philip E. Bourne,et al. The Mycobacterium tuberculosis Drugome and Its Polypharmacological Implications , 2010, PLoS Comput. Biol..
[14] George Papadatos,et al. The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..
[15] F. Spyrakis,et al. Expanding the chemical space of human serine racemase inhibitors. , 2015, Bioorganic & medicinal chemistry letters.
[16] Gabriele Cruciani,et al. Modeling Phospholipidosis Induction: Reliability and Warnings , 2013, J. Chem. Inf. Model..
[17] Bin Chen,et al. Gaining Insight into Off-Target Mediated Effects of Drug Candidates with a Comprehensive Systems Chemical Biology Analysis , 2009, J. Chem. Inf. Model..
[18] Nathanael Weill,et al. Alignment-Free Ultra-High-Throughput Comparison of Druggable Protein-Ligand Binding Sites , 2010, J. Chem. Inf. Model..
[19] Yoshihiro Yamanishi,et al. Predicting drug side-effect profiles: a chemical fragment-based approach , 2011, BMC Bioinformatics.
[20] Gabriele Cruciani,et al. A Common Reference Framework for Analyzing/Comparing Proteins and Ligands. Fingerprints for Ligands And Proteins (FLAP): Theory and Application , 2007, J. Chem. Inf. Model..
[21] Giorgio Palù,et al. Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase , 2012, Proceedings of the National Academy of Sciences.
[22] Keunwan Park,et al. Predicting the multi-modal binding propensity of small molecules: towards an understanding of drug promiscuity. , 2009, Molecular bioSystems.
[23] Maria Paola Costi,et al. Ligand-based virtual screening and ADME-tox guided approach to identify triazolo-quinoxalines as folate cycle inhibitors. , 2010, Bioorganic & medicinal chemistry.
[24] Dusanka Janezic,et al. ProBiS algorithm for detection of structurally similar protein binding sites by local structural alignment , 2010, Bioinform..
[25] Stéphanie Pérot,et al. Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery. , 2010, Drug discovery today.
[26] C. Chong,et al. New uses for old drugs , 2007, Nature.
[27] Maria Paola Costi,et al. The inhibition of extended spectrum β-lactamases: hits and leads. , 2014, Current medicinal chemistry.
[28] Zhongming Zhao,et al. Toward Repurposing Metformin as a Precision Anti-Cancer Therapy Using Structural Systems Pharmacology , 2016, Scientific Reports.
[29] H. Wolfson,et al. Recognition of Functional Sites in Protein Structures☆ , 2004, Journal of Molecular Biology.
[30] P. Bork,et al. A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.
[31] Pankaj Agarwal,et al. Systematic Drug Repositioning Based on Clinical Side-Effects , 2011, PloS one.
[32] Gabriele Ausiello,et al. Structural motifs recurring in different folds recognize the same ligand fragments , 2009, BMC Bioinformatics.
[33] Laetitia Martin-Chanas,et al. Identify drug repurposing candidates by mining the Protein Data Bank , 2011, Briefings Bioinform..
[34] Edward Chu,et al. Thymidylate synthase inhibitors as anticancer agents: from bench to bedside , 2003, Cancer Chemotherapy and Pharmacology.
[35] L. Lebioda,et al. Human thymidylate synthase is in the closed conformation when complexed with dUMP and raltitrexed, an antifolate drug. , 2001, Biochemistry.
[36] Wolfgang Guba,et al. Development of a virtual screening method for identification of "frequent hitters" in compound libraries. , 2002, Journal of medicinal chemistry.
[37] John P. Overington,et al. PPDMs—a resource for mapping small molecule bioactivities from ChEMBL to Pfam-A protein domains , 2014, Bioinform..
[38] J. Bajorath,et al. Compound promiscuity: what can we learn from current data? , 2013, Drug discovery today.
[39] P. Bork,et al. Drug Target Identification Using Side-Effect Similarity , 2008, Science.
[40] Kalidas Yeturu,et al. PocketMatch: A new algorithm to compare binding sites in protein structures , 2008, BMC Bioinformatics.
[41] Lydia Siragusa,et al. BioGPS Descriptors for Rational Engineering of Enzyme Promiscuity and Structure Based Bioinformatic Analysis , 2014, PloS one.
[42] Yoshihiro Yamanishi,et al. Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework , 2010, Bioinform..
[43] David S. Wishart,et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..
[44] Roded Sharan,et al. An Algorithmic Framework for Predicting Side Effects of Drugs , 2011, J. Comput. Biol..
[45] A. Hopkins. Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.
[46] Pietro Cozzini,et al. Isozyme-Specific Ligands for O-acetylserine sulfhydrylase, a Novel Antibiotic Target , 2013, PloS one.
[47] A. Barabasi,et al. Drug—target network , 2007, Nature Biotechnology.
[48] Stefan Schmitt,et al. Do structurally similar ligands bind in a similar fashion? , 2006, Journal of medicinal chemistry.
[49] Lydia Siragusa,et al. BioGPS: The Music for the Chemo‐ and Bioinformatics Walzer , 2014, Molecular informatics.
[50] Andrew L. Hopkins,et al. Drug discovery: Predicting promiscuity , 2009, Nature.
[51] Russ B. Altman,et al. Using Multiple Microenvironments to Find Similar Ligand-Binding Sites: Application to Kinase Inhibitor Binding , 2011, PLoS Comput. Biol..
[52] Russ B Altman,et al. PharmGKB: a logical home for knowledge relating genotype to drug response phenotype , 2007, Nature Genetics.
[53] Gareth J Waldron,et al. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling , 2012, Nature Reviews Drug Discovery.
[54] Yoshihiro Yamanishi,et al. DINIES: drug–target interaction network inference engine based on supervised analysis , 2014, Nucleic Acids Res..
[55] David W. Ritchie,et al. GESSE: Predicting Drug Side Effects from Drug-Target Relationships , 2015, J. Chem. Inf. Model..
[56] M Pastor,et al. VolSurf: a new tool for the pharmacokinetic optimization of lead compounds. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[57] Patrick Aloy,et al. Analysis of chemical and biological features yields mechanistic insights into drug side effects. , 2013, Chemistry & biology.
[58] T K Attwood,et al. OWL--a non-redundant composite protein sequence database. , 1994, Nucleic acids research.
[59] T. Ashburn,et al. Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.
[60] L. Goracci,et al. New linezolid-like 1,2,4-oxadiazoles active against Gram-positive multiresistant pathogens. , 2013, European journal of medicinal chemistry.
[61] Ziding Zhang,et al. Similarity networks of protein binding sites , 2005, Proteins.
[62] Maria Paola Costi,et al. Inhibitor of ovarian cancer cells growth by virtual screening: a new thiazole derivative targeting human thymidylate synthase. , 2012, Journal of medicinal chemistry.
[63] W. Pearson. Rapid and sensitive sequence comparison with FASTP and FASTA. , 1990, Methods in enzymology.
[64] Regina Z. Cer,et al. IC50-to-Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding , 2009, Nucleic Acids Res..
[65] G. Cruciani,et al. Hydrogen bonding interactions of covalently bonded fluorine atoms: from crystallographic data to a new angular function in the GRID force field. , 2004, Journal of medicinal chemistry.
[66] Gergely Zahoránszky-Köhalmi,et al. Drug Effect Prediction by Polypharmacology-Based Interaction Profiling , 2012, J. Chem. Inf. Model..
[67] P. Goodford. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.
[68] L. Pinna,et al. Protein kinase CK2 ("casein kinase-2") and its implication in cell division and proliferation. , 1997, Progress in cell cycle research.
[69] P. Shannon,et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.
[70] G. Klebe,et al. A new method to detect related function among proteins independent of sequence and fold homology. , 2002, Journal of molecular biology.
[71] Susumu Goto,et al. KEGG for representation and analysis of molecular networks involving diseases and drugs , 2009, Nucleic Acids Res..
[72] L. Goracci,et al. Human Cytomegalovirus Inhibitor AL18 Also Possesses Activity against Influenza A and B Viruses , 2012, Antimicrobial Agents and Chemotherapy.
[73] Maria Paola Costi,et al. Protein–protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase , 2011, Proceedings of the National Academy of Sciences.
[74] G. V. Paolini,et al. Global mapping of pharmacological space , 2006, Nature Biotechnology.
[75] Pietro Cozzini,et al. Targeting Cystalysin, a Virulence Factor of Treponema denticola‐Supported Periodontitis , 2014, ChemMedChem.
[76] Maria Paola Costi,et al. Antibacterial agent discovery using thymidylate synthase biolibrary screening. , 2006, Journal of medicinal chemistry.
[77] Jie Li,et al. Prediction of Polypharmacological Profiles of Drugs by the Integration of Chemical, Side Effect, and Therapeutic Space , 2013, J. Chem. Inf. Model..
[78] Tudor I. Oprea,et al. Drug Repurposing: Far Beyond New Targets for Old Drugs , 2012, The AAPS Journal.
[79] L. Goracci,et al. Evaluating the risk of phospholipidosis using a new multidisciplinary pipeline approach. , 2015, European journal of medicinal chemistry.
[80] Michael Schroeder,et al. Drug Promiscuity in PDB: Protein Binding Site Similarity Is Key , 2013, PloS one.
[81] Philip E. Bourne,et al. Drug Off-Target Effects Predicted Using Structural Analysis in the Context of a Metabolic Network Model , 2010, PLoS Comput. Biol..
[82] D. Fairlie,et al. Comparing sixteen scoring functions for predicting biological activities of ligands for protein targets. , 2015, Journal of molecular graphics & modelling.
[83] P. Johnston,et al. Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.
[84] Gabriele Cruciani,et al. BioGPS: Navigating biological space to predict polypharmacology, off‐targeting, and selectivity , 2015, Proteins.
[85] Maria Paola Costi,et al. Improving specificity vs bacterial thymidylate synthases through N-dansyl modulation of didansyltyrosine. , 2005, Journal of medicinal chemistry.